We are live on ! Find out more
ARRY icon

Array Biopharma
ARRY

Delisted

ARRY was delisted on the 29th of July, 2019.

187 hedge funds and large institutions have $1.49B invested in Array Biopharma in 2017 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 61 increasing their positions, 61 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

119% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 21

34% more capital inflows, than outflows

Capital inflows: $353M | Capital outflows: $263M

12% more funds holding

Funds holding: 167 → 187 (+20)

3.6% more ownership

Funds ownership: 95.04% → 98.64% (+3.6%)

10% more call options, than puts

Call options by funds: $30.6M | Put options by funds: $27.9M

0% more repeat investments, than reductions

Existing positions increased: 61 | Existing positions reduced: 61

33% less funds holding in top 10

Funds holding in top 10: 6 → 4 (-2)

Holders
187
Holders Change
+20
Holders Change %
+11.98%
% of All Funds
4.63%
Holding in Top 10
4
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-33.33%
% of All Funds
0.1%
New
46
Increased
61
Reduced
61
Closed
21
Calls
$30.6​M
Puts
$27.9​M
Net Calls
+$2.74​M
Net Calls Change
-⁠$2.54​M

ARRY Hedge Fund Activity: Q1 2017 in Review

187 of the 4,036 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma (ARRY) for Q1 2017, worth a combined $1.49B — up 5.9% from $1.41B a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new ARRY positions and 21 closed out — a net gain of 25 holders — while 61 added to existing stakes and 61 trimmed.

The largest buyer was Vanguard Group, adding an estimated $65.5M. The largest seller was Redmile Group, cutting an estimated $41M.

  • 187 institutional investors held Array Biopharma (ARRY) as of Q1 2017, up from 167 in Q4 2016.
  • Funds reported $1.49B of Array Biopharma stock for Q1 2017, up 5.9% quarter-over-quarter.
  • 46 funds opened new Array Biopharma positions in Q1 2017 and 21 closed out, a net change of +25 holders.
  • The largest Array Biopharma buyer in Q1 2017 was Vanguard Group, an estimated $65.5M added.
  • The largest Array Biopharma seller in Q1 2017 was Redmile Group, an estimated $41M sold.

Based on aggregated 13F filings for Q1 2017.